J Dermatolog Treat. 2023 Dec;34(1):2193662. doi: 10.1080/09546634.2023.2193662. Epub 2023 Mar 20.
We, the Editors and Publisher of , have retracted the following article:Li Luan & Chengzhi Lv (2023) Secukinumab-induced paradoxical skin lesions, but successful treatment with tofacitinib in SAPHO syndrome: a case report, , DOI: 10.1080/09546634.2023.2193662Since publication of the article, concerns were raised by a reader regarding the lack of recorded patient consent to publish. Upon further investigation, it was determined that written consent for the publication was not obtained by the authors. The authors were contacted for an explanation and confirmed written consent for the publication was not obtained.As this represents a breach of the journal's editorial policies, we are therefore retracting the article. The corresponding author listed in this publication has been informed.We have been informed in our decision-making by our editorial policies and the COPE guidelines.The retraction article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted'.
我们，作为《》的编辑和出版者，已经撤回了以下文章：李栾和吕承志（2023 年）司库奇尤单抗诱导的 SAPHO 综合征的矛盾性皮肤病变，但托法替布治疗成功：一例报告，DOI：10.1080/09546634.2023.2193662。自该文章发表以来，一位读者对缺乏记录患者同意发表的问题提出了关注。经过进一步调查，确定作者未获得书面同意发表。作者被联系以解释情况，确认未获得书面同意发表。由于这代表了期刊编辑政策的违反，因此我们撤回了这篇文章。本文的通讯作者已被告知。我们在决策过程中遵循了我们的编辑政策和 COPE 指南。撤稿文章将继续在线以保持学术记录，但每页都会被数字水印标记为“已撤稿”。
